ABSTRACT
MicroRNAs (miRNAs) are short non-coding RNA species which are important post-transcriptional regulators of gene expression and play an important role in the pathogenesis of diabetic nephropathy. miRNAs are present in urine in a remarkably stable form packaged in extracellular vesicles, predominantly exosomes. In the present study, urinary exosomal miRNA profiling was conducted in urinary exosomes obtained from 8 healthy controls (C), 8 patients with type II diabetes (T2D) and 8 patients with type II diabetic nephropathy (DN) using Agilent´s miRNA microarrays. In total, the expression of 16 miRNA species was deregulated (>2-fold) in DN patients compared to healthy donors and T2D patients: the expression of 14 miRNAs (miR-320c, miR-6068, miR-1234-5p, miR-6133, miR-4270, miR-4739, miR-371b-5p, miR-638, miR-572, miR-1227-5p, miR-6126, miR-1915-5p, miR-4778-5p and miR-2861) was up-regulated whereas the expression of 2 miRNAs (miR-30d-5p and miR-30e-5p) was down-regulated. Most of the deregulated miRNAs are involved in progression of renal diseases. Deregulation of urinary exosomal miRNAs occurred in micro-albuminuric DN patients but not in normo-albuminuric DN patients. We used qRT-PCR based analysis of the most strongly up-regulated miRNAs in urinary exosomes from DN patients, miRNAs miR-320c and miR-6068. The correlation of miRNA expression and micro-albuminuria levels could be replicated in a confirmation cohort. In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-ß-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
Subject(s)
Albuminuria/metabolism , Diabetes Mellitus, Type 2/metabolism , Diabetic Nephropathies/metabolism , Exosomes/metabolism , MicroRNAs/urine , Adult , Aged , Albuminuria/genetics , Albuminuria/urine , Diabetes Mellitus, Type 2/genetics , Diabetes Mellitus, Type 2/urine , Diabetic Nephropathies/genetics , Diabetic Nephropathies/urine , Exosomes/genetics , Female , Humans , Male , Middle Aged , Signal Transduction/physiology , Young AdultABSTRACT
AIM: To investigate the efficacy of the peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, AVE8134, in cellular and experimental models of cardiac dysfunction and heart failure. METHODS: In Sprague Dawley rats with permanent ligation of the left coronary artery (post-MI), AVE8134 was compared to the PPARgamma agonist rosiglitazone and in a second study to the ACE inhibitor ramipril. In DOCA-salt sensitive rats, efficacy of AVE8134 on cardiac hypertrophy and fibrosis was investigated. Finally, AVE8134 was administered to old spontaneously hypertensive rats (SHR) at a non-blood pressure lowering dose with survival as endpoint. In cellular models, we studied AVE8134 on hypertrophy in rat cardiomyocytes, nitric oxide signaling in human endothelial cells (HUVEC) and LDL-uptake in human MonoMac-6 cells. RESULTS: In post-MI rats, AVE8134 dose-dependently improved cardiac output, myocardial contractility and relaxation and reduced lung and left ventricular weight and fibrosis. In contrast, rosiglitazone exacerbated cardiac dysfunction. Treatment at AVE8134 decreased plasma proBNP and arginine and increased plasma citrulline and urinary NOx/creatinine ratio. In DOCA rats, AVE8134 prevented development of high blood pressure, myocardial hypertrophy and cardiac fibrosis, and ameliorated endothelial dysfunction. Compound treatment increased cardiac protein expression and phosphorylation of eNOS. In old SHR, treatment with a low dose of AVE8134 improved cardiac and vascular function and increased life expectancy without lowering blood pressure. AVE8134 reduced phenylephrine-induced hypertrophy in adult rat cardiomyocytes. In HUVEC, Ser-1177-eNOS phosphorylation but not eNOS expression was increased. In monocytes, AVE8134 increased the expression of CD36 and the macrophage scavenger receptor 1, resulting in enhanced uptake of oxidized LDL. CONCLUSION: The PPARalpha agonist AVE8134 prevents post-MI myocardial hypertrophy, fibrosis and cardiac dysfunction. AVE8134 has beneficial effects against hypertension-induced organ damages, resulting in decreased mortality. The compound exerts its protective properties by a direct effect on cardiomyocyte hypertrophy, but also indirectly via monocyte signaling and increased endothelial NO production.Acta Pharmacologica Sinica (2009) 30: 935-946; doi: 10.1038/aps.2009.58; published online 8 June 2009.
Subject(s)
Benzoates/therapeutic use , Cardiotonic Agents/therapeutic use , Heart Failure , Oxazoles/therapeutic use , PPAR alpha/agonists , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Animals , Benzoates/chemistry , Benzoates/metabolism , Biomarkers/metabolism , Cardiotonic Agents/chemistry , Cardiotonic Agents/metabolism , Cell Line , Disease Progression , Heart Failure/drug therapy , Heart Failure/pathology , Heart Failure/physiopathology , Hemodynamics , Humans , Hypoglycemic Agents/therapeutic use , Male , Molecular Structure , Nitric Oxide Synthase Type III/metabolism , Oxazoles/chemistry , Oxazoles/metabolism , PPAR alpha/metabolism , Ramipril/therapeutic use , Rats , Rats, Inbred SHR , Rats, Sprague-Dawley , Rosiglitazone , Survival Rate , Thiazolidinediones/therapeutic useABSTRACT
The mitochondrial pyruvate dehydrogenase complex (PDC) is inactivated in many tissues during starvation and diabetes. We investigated carbohydrate oxidation (CHO) and the regulation of the PDC in lean and obese Zucker diabetic fatty (ZDF) rats during fed and starved conditions as well as during an oral glucose load without and with pharmacologically reduced levels of free fatty acids (FFA) to estimate the relative contribution of FFA on glucose tolerance, CHO, and PDC activity. The increase in total PDC activity (20-45%) was paralleled by increased protein levels ( approximately 2-fold) of PDC subunits in liver and muscle of obese ZDF rats. Pyruvate dehydrogenase kinase-4 (PDK4) protein levels were higher in obese rats, and consequently PDC activity was reduced. Although PDK4 protein levels were rapidly downregulated (57-62%) in both lean and obese animals within 2 h after glucose challenge, CHO over 3 h as well as the peak of PDC activity (1 h after glucose load) in liver and muscle were significantly lower in obese rats compared with lean rats. Similar differences were obtained with pharmacologically suppressed FFA by nicotinic acid, but with significantly improved glucose tolerance in obese rats, as well as increased CHO and delta increases in PDC activity (0-60 min) both in muscle and liver. These results demonstrated the suppressive role of FFA acids on the measured parameters. Furthermore, the results clearly demonstrate a rapid reactivation of PDC in liver and muscle of lean and obese rats after a glucose load and show that PDC activity is significantly lower in obese ZDF rats.
Subject(s)
Diabetes Mellitus, Type 2/metabolism , Insulin Resistance/physiology , Obesity/metabolism , Protein Serine-Threonine Kinases/metabolism , Pyruvate Dehydrogenase Complex/metabolism , Animals , Blood Glucose/metabolism , Fatty Acids, Nonesterified/metabolism , Glucose Tolerance Test , Hyperinsulinism/metabolism , Male , Oxidation-Reduction , Pyruvate Dehydrogenase Acetyl-Transferring Kinase , Rats , Rats, Zucker , Starvation/metabolismABSTRACT
BACKGROUND: Vasopeptidase inhibition has been shown to be an effective antihypertensive principle but its long-term effects on hypertensive target organ damage are not known. We investigated the myocardial, vascular and renal effects of chronic vasopeptidase inhibition in arterial hypertension. METHODS AND RESULTS: One hundred and thirty-nine male spontaneously hypertensive rats aged 15 months were treated chronically with either the pure angiotensin-converting enzyme (ACE) inhibitor, ramipril (1 mg/kg/d in drinking water, n=46), or the vasopeptidase inhibitor AVE7688 (30 mg/kg/d in chow, n=46), or placebo (n=47) and followed up until they died. After six months, both ramipril and AVE7688 had markedly reduced plasma ACE activity, normalised blood pressure (BP), reduced left ventricular mass and improved systolic function to similar extents. Acetylcholine mediated relaxation of aortic rings was improved by both ramipril and AVE7688. There was substantial albuminuria in the placebo group (albumin-to-creatinine ratio 107+/-54 microg/mg), which was significantly reduced by ramipril to 57+/-34 microg/mg, and practically abolished in the AVE7688 group (22+/-12 microg/mg, p<0.05 vs. placebo and ramipril). Tubulo-interstitial damage (semi-quantitative score) was significantly reduced by AVE7688 and ramipril. Overall mortality was markedly reduced in the ramipril and AVE7688 groups (13% and 16% at six months, respectively), both p<0.05 vs. placebo (71%). CONCLUSIONS: Vasopeptidase inhibition effectively controls BP and reduces myocardial, vascular and renal target organ damage, resulting in a markedly prolonged survival. At similar degrees of plasma ACE inhibition, AVE7688 compared to ramipril offers superior protection against hypertensive kidney damage.
Subject(s)
Blood Pressure/drug effects , Heterocyclic Compounds, 3-Ring/pharmacology , Hypertension/enzymology , Peptide Hydrolases/drug effects , Protease Inhibitors/pharmacology , Albuminuria/diagnosis , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Animals , Aorta/drug effects , Aorta/pathology , Endothelium, Vascular/drug effects , Fibrosis/prevention & control , Hypertension, Renal/prevention & control , Kidney/drug effects , Kidney/pathology , Male , Myocardium/pathology , Peptidyl-Dipeptidase A/blood , Placebos/pharmacology , Ramipril/pharmacology , Rats , Rats, Inbred SHR , Ventricular Function, Left/drug effectsABSTRACT
Intramyocellular lipid content (IMCL) serves as a good biomarker of skeletal muscle insulin resistance (IR). However, intracellular fatty acid metabolites [malonyl-CoA, long-chain acyl-CoA (LCACoA)] rather than IMCL are considered to be responsible for IR. This study aimed to investigate dynamics of IMCL and fatty acid metabolites during fed-to-starved-to-refed transition in lean and obese (IR) Zucker diabetic fatty rats in the following different muscle types: soleus (oxidative), extensor digitorum longus (EDL, intermediary), and white tibialis anterior (wTA, glycolytic). In the fed state, IMCL was significantly elevated in obese compared with lean rats in all three muscle types (soleus: 304%, EDL: 333%, wTA: 394%) in the presence of elevated serum triglycerides but similar levels of free fatty acids (FFA), malonyl-CoA, and total LCACoAs. During starvation, IMCL in soleus remained relatively constant, whereas in both rat groups IMCL increased significantly in wTA and EDL after comparable dynamics of starvation-induced FFA availability. The decreases of malonyl-CoA in wTA and EDL during starvation were more pronounced in lean than in obese rats, although there were no changes in soleus muscles for both groups. The concomitant increase in IMCL with the fall of malonyl-CoA support the concept that, as a reaction to starvation-induced FFA availability, muscle will activate lipid oxidation more the lower its oxidative capacity and then store the rest as IMCL.
Subject(s)
Fatty Acids/metabolism , Insulin Resistance/physiology , Muscle, Skeletal/metabolism , 3-Hydroxyacyl CoA Dehydrogenases/metabolism , Animals , Blood Glucose/metabolism , Body Weight/physiology , Fatty Acids/analysis , Fatty Acids, Nonesterified/blood , Fatty Acids, Unsaturated/analysis , Glucose Clamp Technique , Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism , Glycogen Phosphorylase/metabolism , Hexokinase/metabolism , Insulin/blood , Ketone Bodies/blood , Lipids/analysis , Male , Malonyl Coenzyme A/metabolism , Muscle Fibers, Fast-Twitch/chemistry , Muscle Fibers, Fast-Twitch/enzymology , Muscle Fibers, Fast-Twitch/metabolism , Muscle Fibers, Slow-Twitch/chemistry , Muscle Fibers, Slow-Twitch/enzymology , Muscle Fibers, Slow-Twitch/metabolism , Muscle, Skeletal/chemistry , Muscle, Skeletal/enzymology , Rats , Rats, Zucker , Triglycerides/bloodABSTRACT
1 We investigated the single vs the combined long-term inhibition of Na(+)-H(+) exchanger-1 (NHE-1) and ACE in rats with congestive heart failure induced by myocardial infarction (MI). 2 Rats with MI were randomized to receive either placebo, cariporide (3000 p.p.m. via chow), ramipril (1 mg kg(-1) day(-1) via drinking water) or their combination for 18 weeks starting on day 3 after surgery. 3 Cardiac morphology and function was assessed by echocardiography and by means of a 2.0 F conductance catheter to determine left ventricular (LV) pressure volume relationships. 4 MI for 18 weeks resulted in an increase in LV end-diastolic diameter (LVDed) in the placebo-treated group when compared to sham (placebo: 1.1+/-0.04 cm; sham: 0.86+/-0.01; P<0.05). Combined inhibition of NHE-1 and ACE, but not the monotherapies, significantly reduced LVDed (1.02+/-0.02 cm). 5 Preload recruitable stroke work (PRSW), dp/dt(max) (parameter of systolic function) and end-diastolic pressure volume relationship (EDPVR, diastolic function) were significantly impaired in placebo-treated MI group (PRSW: 39+/-7 mmHg; dp/dt(max): 5185+/-363 mmHg s(-1); EDPVR: 0.042+/-0.001 mmHg microl(-1); all P<0.05). Cariporide treatment significantly improved PRSW (64+/-7 mmHg), dp/dt(max) (8077+/-525 mmHg s(-1)) and EDPVR (0.026+/-0.014 mmHg microl(-1)), and reduced cardiac hypertrophy in rats with MI. Combined inhibition of NHE-1 and ACE had even a more pronounced effect on PRSW (72+/-5 mmHg) and EDPVR (0.026+/-0.014 mmHg microl(-1)), as well as cardiac hypertrophy that, however, did not reach statistical significance compared to cariporide treatment alone. 6 The NHE-1 inhibitor cariporide significantly improved LV remodeling and function in rats with congestive heart failure induced by MI. The effect of cariporide was comparable or tended to be stronger (e.g. systolic function) compared to ramipril. Combined treatment with cariporide and ramipril tended to be more effective on LV remodeling in rats with heart failure than the single treatments. Thus, inhibition of the NHE-1 may be a promising novel therapeutic approach for the treatment of congestive heart failure.
Subject(s)
Angiotensin-Converting Enzyme Inhibitors/pharmacology , Heart Failure/metabolism , Myocardial Infarction/complications , Peptidyl-Dipeptidase A/drug effects , Ramipril/pharmacology , Sodium-Hydrogen Exchangers/antagonists & inhibitors , Animals , Guanidines/pharmacology , Heart/drug effects , Heart Failure/complications , Heart Failure/enzymology , Lung/drug effects , Male , Organ Size , Rats , Rats, Sprague-Dawley , Sulfones/pharmacologyABSTRACT
The aim of this study was to assess the effects of the Na+-H+ exchange inhibitor cariporide on left ventricular (LV) morphology and function as well as inflammation in rabbits with heart failure. Rabbits with myocardial infarction (MI) and sham controls were randomized to receive either standard chow or chow supplemented with cariporide for 9 weeks. LV morphology was determined by echocardiography. LV systolic and diastolic function was assessed under load-dependent and -independent conditions by analysis of LV pressure-volume loops using piezo-electric crystals. Plasma concentrations of C-reactive protein and aldosterone were measured. Rabbits with MI developed LV dilatation that was reduced by cariporide. Systolic and diastolic LV function was impaired in rabbits with MI when compared to sham, as indicated by a decreased dP/dtmax (MI: 3537 +/- 718 mmHg s(-1), sham: 5839 +/- 247 mmHg s(-1), P < 0.05), the load-independent preload recruitable stroke work (PRSW)(MI: 22 +/-7 mmHg, sham: 81 +/- 23 mmHg, P < 0.05) and a reduction in the time constant of relaxation tau (tau) (MI: 27+/-1 ms, sham: 17+/-1 ms, P < 0.05), and significantly improved by cariporide (dP/dtmax: 4586 +/- 374 mmHg s(-1), PRSW: 67 +/- 18 mmHg, tau: 20 +/- 2 ms; P < 0.05 vs MI/control). Induction of MI was associated with an increase in aldosterone and CRP, indicating activation of the neurohormonal and the inflammatory system that were largely reduced by cariporide. Cariporide improves LV morphology and function post MI and suppresses inflammation and neurohormonal activation in congestive heart failure (CHF). Na+-H+ exchange inhibition may represent a new pharmaceutical approach for the treatment of CHF.
Subject(s)
C-Reactive Protein/analysis , Guanidines/pharmacology , Heart Failure/drug therapy , Myocardial Infarction/physiopathology , Sodium-Hydrogen Exchangers/antagonists & inhibitors , Sulfones/pharmacology , Aldosterone/blood , Animals , C-Reactive Protein/metabolism , Electrocardiography , Heart Failure/etiology , Heart Failure/physiopathology , Inflammation/blood , Inflammation/drug therapy , Male , Myocardial Infarction/complications , Myocardial Infarction/mortality , Myocardium/pathology , Rabbits , Survival Rate , Time Factors , Ventricular Function, Left/drug effectsABSTRACT
Basement membranes generally determine different tissue compartments in complex organs, such as skin, playing not only an important structural but also a regulatory role. We have previously demonstrated the formation of a regular basement membrane in organotypic three-dimensional (3D)-cocultures of human skin keratinocytes and fibroblasts by indirect immunofluorescence and transmission electron microscopy. In this assembly process, cross-linking of type IV collagen and the laminin gamma1 chain by nidogen is considered a crucial step. For a functional proof, we have now competitively inhibited nidogen binding to laminin in 3D-cocultures with a recombinant laminin gamma1 fragment (gamma1III3-5 module) spanning this binding site. Repeated treatment abolished the deposition of nidogen at the epithelial-matrix interface but also greatly perturbed the presence of other matrix constituents such as laminin and perlecan. This effect persisted over the entire observation period of 10 to 21 days. In contrast, some components of the basement membrane zone were only moderately affected, with the laminin-5 isoform (gamma2 chain), type IV collagen and integrin alpha6ss4 still showing a distinct staining at their regular position, when seen by light microscopy. Furthermore, epidermal morphology and differentiation remained largely normal as indicated by the regular location of keratins K1/K10 and also of late differentiation markers. Ultrastructural examination demonstrated that the gamma1 fragment completely suppressed any formation of basement membrane structures (lamina densa) and also of hemidesmosomal adhesion complexes. As a consequence of hemidesmosome deficiency, keratin filament bundles were not attached to the ventral basal cell aspect. These findings were further substantiated by immuno-electron microscopy, revealing either loss or drastic reduction and dislocation of basement membrane and hemidesmosomal components. Taken together, in this simplified human skin model (representing a 'closed system') a functional link has been demonstrated between compound structures of the extra- and intracellular space at the junctional zone providing a basis to interfere at distinct points and in a controlled fashion.
Subject(s)
Basement Membrane/metabolism , Laminin/metabolism , Membrane Glycoproteins/metabolism , Skin/cytology , Basement Membrane/ultrastructure , Binding Sites , Carrier Proteins/drug effects , Carrier Proteins/metabolism , Carrier Proteins/ultrastructure , Cell Differentiation , Cells, Cultured , Coculture Techniques , Collagen Type IV/drug effects , Collagen Type IV/metabolism , Collagen Type IV/ultrastructure , Cross-Linking Reagents/metabolism , Dose-Response Relationship, Drug , Eukaryotic Initiation Factors , Extracellular Matrix/chemistry , Fluorescent Antibody Technique, Indirect , Hemidesmosomes/ultrastructure , Heparan Sulfate Proteoglycans/metabolism , Humans , Integrin alpha6beta4/drug effects , Integrin alpha6beta4/metabolism , Intermediate Filament Proteins/drug effects , Intermediate Filament Proteins/metabolism , Intermediate Filament Proteins/ultrastructure , Keratin-1 , Keratin-10 , Keratinocytes/metabolism , Keratins/metabolism , Keratins/ultrastructure , Laminin/drug effects , Laminin/genetics , Laminin/pharmacology , Organ Culture Techniques , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Time FactorsABSTRACT
The physiological dynamics of intramyocellular lipids (IMCLs) in different muscle types and of hepatocellular lipids (HepCLs) are still uncertain. The dynamics of IMCLs in the soleus, tibialis anterior, and extensor digitorum longus (EDL) muscles and HepCL during fed, 12- to 72-h starved, and refed conditions were measured in vivo by (1)H-magnetic resonance spectroscopy (MRS) in Wistar rats. Despite significant elevations of free fatty acids (FFAs) during starvation, HepCLs and IMCLs in soleus remained constant. In tibialis anterior and EDL, however, IMCLs increased significantly by 170 and 450% after 72 h of starvation, respectively. After refeeding, elevated IMCLs dropped immediately in both muscles. Total muscle long-chain acyl-CoAs (LCACoAs) remained constant during the study period. Hepatic palmitoleoyl-CoA (C16:1) decreased significantly during starvation while total hepatic LCACoAs increased significantly. Consistent with constant values for FFAs, HepCLs, IMCLs, and muscle LCACoAs from 12-72 h of starvation, insulin sensitivity did not change. We conclude that during starvation-induced adipocytic lipolysis, oxidative muscles dispose elevated FFAs by oxidation, while nonoxidative ones neutralize FFAs by reesterification. Both mechanisms might prevent impairment of insulin signaling by maintaining low levels of LCACoAs. Hepatic palmitoleoyl-CoA might have a special role in lipid metabolism due to its unique dynamic profile during starvation.
Subject(s)
Lipid Metabolism , Liver Glycogen/metabolism , Liver/metabolism , Muscle, Skeletal/metabolism , Starvation/metabolism , Animals , Blood Glucose/metabolism , Glucose Clamp Technique , Male , Organ Specificity , Rats , Rats, Wistar , Time Factors , Triglycerides/metabolismABSTRACT
BACKGROUND: Blocking the renin-angiotensin system is an established therapeutic principle in diabetic nephropathy. We investigated whether inhibition of both neutral endopeptidase and ACE (vasopeptidase inhibition) can prevent functional and morphological features of nephropathy in the Zucker diabetic fatty (ZDF) rat, an animal model of type II diabetes. METHODS: Homozygous (fa/fa) ZDF rats (each n=15) aged 10 weeks were treated with placebo, ramipril (1 mg/kg/day in drinking water), or the vasopeptidase inhibitor AVE7688 (45 mg/kg/day in chow). Metabolic parameters and renal function (metabolic cages) were assessed at baseline (age 10 weeks), and at age 17, 27, and 37 weeks. Twenty heterozygous animals (fa/-) served as lean, nondiabetic controls. At age 37 weeks, the animals were sacrificed and the kidneys analyzed histopathologically. RESULTS: Overt diabetes mellitus (blood glucose >20 mmol/l) was established at age 17 weeks in all homozygous ZDF rats. In the placebo group, urinary protein excretion increased progressively from 8+/-1 (baseline) to 342+/-56 mg/kg/day (week 37) whereas diabetes and proteinuria were absent in the lean control group. Ramipril tended to reduce albuminuria and morphological damage (p=ns) but AVE7688 virtually prevented albuminuria (33+/-12 mg/kg/day, p<0.05 vs. ZDF placebo) and drastically reduced the incidence and severity of glomerulosclerosis and tubulointerstitial damage. CONCLUSIONS: In ZDF rats, development of diabetes mellitus is accompanied by functional and morphological kidney damage that resembles human diabetic nephropathy. Diabetic nephropathy can be prevented by chronic vasopeptidase inhibition.
Subject(s)
Diabetic Nephropathies/drug therapy , Heterocyclic Compounds, 3-Ring/therapeutic use , Prodrugs , Protease Inhibitors/therapeutic use , Albuminuria/drug therapy , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Animals , Area Under Curve , Benzazepines/blood , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/pathology , Diabetic Nephropathies/blood , Diabetic Nephropathies/pathology , Enzyme Inhibitors/therapeutic use , Half-Life , Kidney/pathology , Male , Peptidyl-Dipeptidase A/blood , Pyridines/blood , Ramipril/therapeutic use , Rats , Rats, ZuckerABSTRACT
The investigation of intramyocellular lipids (IMCLs) with proton MR spectroscopy ((1)H-MRS) in humans has recently received increasing attention. IMCL levels correlate with insulin resistance and are affected by diet and exercise, making IMCL an interesting marker for metabolic investigations. In the present in vivo study, the feasibility of using (1)H MRS for the detection of IMCL in rats is demonstrated, and the influence of various factors, such as age, gender, muscle type, and rat strain, on IMCL levels is systematically analyzed. In healthy Wistar and Sprague Dawley (SD) rats, the highest ratios of IMCL/tCr were found in young rats, and IMCL/tCr decreased with increasing age. In addition, IMCL concentration was clearly influenced by gender and muscle type. Insulin-resistant, male, obese, Zucker diabetic fatty (ZDF) rats showed significantly higher IMCL levels than Wistar or SD rats. In conclusion, although IMCL levels are clearly influenced by insulin resistance, several other factors influence IMCL levels, such as age, gender, muscle type, and rat strain. Therefore, when using IMCL as a surrogate marker for insulin resistance, it is necessary to carefully compare results with age- and gender-matched controls, and to use identical conditions.
Subject(s)
Lipids/analysis , Magnetic Resonance Spectroscopy , Muscle, Skeletal/chemistry , Aging/metabolism , Animals , Diabetes Mellitus, Experimental/metabolism , Female , Hindlimb , Insulin Resistance , Male , Muscle Fibers, Skeletal/chemistry , Muscle, Skeletal/cytology , Obesity/metabolism , Rats , Rats, Sprague-Dawley , Rats, Wistar , Rats, ZuckerABSTRACT
Two chickens were immunised with the aminoterminal propeptide of bovine procollagen type III (PIIINP) purified from bovine fetal skin. Both animals developed antibodies binding to either unmodified or iodinated bovine PIIINP, but only one chicken developed antibodies which recognise PIIINP variants in serum. These antibodies were used to establish RIAs to analyze the specificity of these particular antibodies and to compare their specificity with that of published assays, as well as laboratory assay variants utilizing different rabbit and mouse antibodies. In comparison to most anti-PIIINP polyclonal antisera from rabbits the chicken antibodies do not bind to the Col-1 domain of PIIINP, a characteristic which they share with a monoclonal antibody (MAB 238) produced from a mouse immunized with the same antigen. Like the monoclonal antibody, the chicken antibodies exhibit reactivity against intact serum PIIINP and its high molecular weight variants, most probably pN procollagen type III and procollagen type III. While the monoclonal antibody can only be applied to analyze PIIINP in human sera, the avian antibodies show reactivity to the antigen in both, human and rat sera. The chicken anti PIIINP antibodies described in this study may become a powerful tool to quantitative PIIINP in serum of patients with liver fibrosis and in serum from experimental rat models of fibrogenesis. The fact that both can be analyzed with the same assay, gives, for the first time, the opportunity for a direct comparison of the results from human and rat studies designed to evaluate the action of antifibrotic agents.